Solid form screening--a review.

Solid form screening, the activity of generating and analysing different solid forms of an active pharmaceutical ingredient (API), has become an essential part of drug development. The multi-step screening process needs to be designed, performed and evaluated carefully, since the decisions made based on the screening may have consequences on the whole lifecycle of a pharmaceutical product. The selection of the form for development is made after solid form screening. The selection criteria include not only pharmaceutically relevant properties, such as therapeutic efficacy and processing characteristics, but also intellectual property (IP) issues. In this paper, basic principles of solid form screening are reviewed, including the methods used in experimental screening (generation, characterisation and analysis of solid forms, data mining tools, and high-throughput screening technologies) as well as basics of computational methods. Differences between solid form screening strategies of branded and generic pharmaceutical manufacturers are also discussed.

[1]  K. Shankland,et al.  Control and prediction of packing motifs: a rare occurrence of carbamazepine in a catemeric configuration , 2006 .

[2]  Orn Almarsson,et al.  Salt Selection and Simultaneous Polymorphism Assessment via High-Throughput Crystallization: The Case of Sertraline , 2003 .

[3]  R. Davey,et al.  Hydration in molecular crystals: A Cambridge structural database analysis , 2003 .

[4]  T. Threlfall Analysis of organic polymorphs. A review , 1995 .

[5]  Y. Ozaki,et al.  Comparative determination of polymorphs of indomethacin in powders and tablets by chemometrical near-infrared spectroscopy and X-ray powder diffractometry , 2003, AAPS PharmSciTech.

[6]  E. Boldyreva,et al.  Effect of High Pressure on the Polymorphs of Paracetamol , 2002 .

[7]  A. Matzger,et al.  Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. , 2003, Journal of pharmaceutical sciences.

[8]  Jeremy I. Bulow,et al.  The Gaming of Pharmaceutical Patents , 2003, Innovation Policy and the Economy.

[9]  D. Grant,et al.  Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. , 2001, Journal of pharmaceutical sciences.

[10]  K. Kachrimanis,et al.  Effects of harvesting and cooling on crystallization and transformation of orthorhombic paracetamol in ethanolic solution. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  K. Morris STRUCTURAL ASPECTS OF HYDRATES AND SOLVATES , 1999 .

[12]  Eric R. Ziegel,et al.  Handbook of Chemometrics and Qualimetrics, Part B , 2000, Technometrics.

[13]  Bruno C. Hancock,et al.  Characteristics and significance of the amorphous state in pharmaceutical systems. , 1997, Journal of pharmaceutical sciences.

[14]  D. Grant THEORY AND ORIGIN OF POLYMORPHISM , 1999 .

[15]  G. P. Stahly Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Cocrystals , 2007 .

[16]  T. C. Lewis,et al.  The polymorphism of progesterone: stabilization of a 'disappearing' polymorph by co-crystallization. , 2007, Journal of pharmaceutical sciences.

[17]  Sarah L Price,et al.  Crystal structure prediction of small organic molecules: a second blind test. , 2002, Acta crystallographica. Section B, Structural science.

[18]  Orn Almarsson,et al.  High-Throughput Surveys of Crystal Form Diversity of Highly Polymorphic Pharmaceutical Compounds , 2003 .

[19]  W. Mccrone,et al.  Pharmaceutical applications of polymorphism. , 1969, Journal of pharmaceutical sciences.

[20]  A. Jaffe,et al.  Innovation policy and the economy , 2001 .

[21]  Lawrence X. Yu,et al.  Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). , 2004, Advanced drug delivery reviews.

[22]  S. Byrn Solid state chemistry of drugs , 1982 .

[23]  M. Otsuka,et al.  Comparative evaluation of the degree of indomethacin crystallinity by chemoinfometrical fourie-transformed near-infrared spectroscopy and conventional powder X-ray diffractiometry , 2000, AAPS PharmSci.

[24]  Low-level determination of polymorph composition in physical mixtures by near-infrared reflectance spectroscopy. , 2001, Journal of pharmaceutical sciences.

[25]  J. Senker,et al.  Polymorphism in benzamide: solving a 175-year-old riddle. , 2007, Angewandte Chemie.

[26]  Ronei Jesus Poppi,et al.  Figures of merit for the determination of the polymorphic purity of carbamazepine by infrared spectroscopy and multivariate calibration. , 2004, Journal of pharmaceutical sciences.

[27]  Changquan Calvin Sun,et al.  Influence of Crystal Structure on the Tableting Properties of Sulfamerazine Polymorphs , 2001, Pharmaceutical Research.

[28]  Jukka Rantanen,et al.  DRIFT-IR for quantitative characterization of polymorphic composition of sulfathiazole , 2005 .

[29]  Peddy Vishweshwar,et al.  Pharmaceutical co-crystals. , 2006, Journal of pharmaceutical sciences.

[30]  Donald E. Williams,et al.  Improved intermolecular force field for molecules containing H, C, N, and O atoms, with application to nucleoside and peptide crystals , 2001, J. Comput. Chem..

[31]  Paul E. Shaw,et al.  Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. , 2002, Journal of the American Chemical Society.

[32]  Barry K. Lavine,et al.  Spectral Pattern Recognition Using Self-Organizing MAPS , 2004, J. Chem. Inf. Model..

[33]  A. Gavezzotti Calculation of Intermolecular Interaction Energies by Direct Numerical Integration over Electron Densities. I. Electrostatic and Polarization Energies in Molecular Crystals , 2002 .

[34]  Jukka Rantanen,et al.  Multivariate data analysis as a fast tool in evaluation of solid state phenomena. , 2006, Journal of pharmaceutical sciences.

[35]  J. Dunitz Are crystal structures predictable? , 2003, Chemical communications.

[36]  Lawrence X. Yu,et al.  Applications of process analytical technology to crystallization processes. , 2004, Advanced drug delivery reviews.

[37]  Donald E. Williams Improved intermolecular force field for crystalline oxohydrocarbons including OHO hydrogen bonding , 2001 .

[38]  Joel Bernstein,et al.  Polymorphism in Molecular Crystals , 2002 .

[39]  Richard D. Braatz,et al.  First-principles and direct design approaches for the control of pharmaceutical crystallization , 2005 .

[40]  Effects of solvent composition and temperature on polymorphism and crystallization behavior of thiazole-derivative , 2002 .

[41]  P Verwer,et al.  A test of crystal structure prediction of small organic molecules. , 2000, Acta crystallographica. Section B, Structural science.

[42]  S. Price The computational prediction of pharmaceutical crystal structures and polymorphism. , 2004, Advanced drug delivery reviews.

[43]  Claus Cornett,et al.  Solvent diversity in polymorph screening. , 2008, Journal of pharmaceutical sciences.

[44]  D. E. Williams,et al.  Improved intermolecular force field for crystalline hydrocarbons containing four- or three-coordinated carbon , 1999 .

[45]  L. Dupont,et al.  Structure cristalline et moléculaire de la progestérone, C21H30O2 , 1972 .

[46]  G A Stephenson,et al.  Characterization of the solid state: quantitative issues. , 2001, Advanced drug delivery reviews.

[47]  A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal , 2003 .

[48]  P. W. Cains,et al.  Sonocrystallization: The Use of Ultrasound for Improved Industrial Crystallization , 2005 .

[49]  S. Price,et al.  An automated parallel crystallisation search for predicted crystal structures and packing motifs of carbamazepine. , 2006, Journal of pharmaceutical sciences.

[50]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[51]  Lawrence X. Yu,et al.  Scientific Considerations of Pharmaceutical Solid Polymorphism in Regulatory Applications , 2006 .

[52]  Wolfgang Beckmann,et al.  Seeding the Desired Polymorph: Background, Possibilities, Limitations, and Case Studies , 2000 .

[53]  David J.W. Grant,et al.  Stabilization of a metastable polymorph of sulfamerazine by structurally related additives , 2002 .

[54]  Bruno C. Hancock,et al.  What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.

[55]  D. E. Williams,et al.  Coulombic interactions in crystalline hydrocarbons , 1974 .

[56]  K. Morris,et al.  Stabilization of a Metastable Polymorph of 4-Methyl-2-nitroacetanilide by Isomorphic Additives , 2001 .

[57]  Paul Geladi,et al.  Principal Component Analysis , 1987, Comprehensive Chemometrics.

[58]  Robert Docherty,et al.  Automation of Solid form Screening Procedures in the Pharmaceutical Industry—How to Avoid the Bottlenecks , 2004 .

[59]  Jukka Rantanen,et al.  Polymorph screening using near-infrared spectroscopy , 2003 .

[60]  K. Takayama,et al.  An accurate quantitative analysis of polymorphs based on artificial neural networks. , 2006, Colloids and surfaces. B, Biointerfaces.

[61]  T. C. Lewis,et al.  A third blind test of crystal structure prediction. , 2005, Acta crystallographica. Section B, Structural science.

[62]  S. Chemburkar,et al.  Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development , 2000 .

[63]  M. Anttila,et al.  Pharmacokinetics and dissolution of two crystalline forms of carbamazepine , 1983 .

[64]  Aditya Mohan Kaushal,et al.  Amorphous drug delivery systems: molecular aspects, design, and performance. , 2004, Critical reviews in therapeutic drug carrier systems.

[65]  Response surface analysis of solution-mediated polymorphic transformation of buspirone hydrochloride. , 2007, Journal of pharmaceutical and biomedical analysis.

[66]  P. Gemperline,et al.  Near-IR Detection of Polymorphism and Process-Related Substances , 1996 .

[67]  Rolf Hilfiker,et al.  POLYMORPHISM , 1945 .

[68]  Leonard J. Chyall,et al.  New solid-state chemistry technologies to bring better drugs to market: knowledge-based decision making , 2007, Expert opinion on drug discovery.

[69]  R. S. Bradley,et al.  349. The vapour pressure and lattice energy of some aromatic ring compounds , 1953 .

[70]  G Nichols,et al.  Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution. , 1998, Journal of pharmaceutical sciences.

[71]  Yadan W. Chen,et al.  Characterization and quantitation of aprepitant drug substance polymorphs by attenuated total reflectance fourier transform infrared spectroscopy. , 2003, Analytical chemistry.

[72]  Kati Pöllänen,et al.  Qualitative in situ analysis of multiple solid-state forms using spectroscopy and partial least squares discriminant modeling. , 2007, Journal of pharmaceutical sciences.

[73]  A. Gavezzotti A solid-state chemist's view of the crystal polymorphism of organic compounds. , 2007, Journal of pharmaceutical sciences.

[74]  R. Hilfiker,et al.  Approaches to Polymorphism Screening , 2006 .

[75]  S. Byrn,et al.  Chemical reactivity in solid-state pharmaceuticals: formulation implications. , 2001, Advanced drug delivery reviews.

[76]  Jonathan M Goodman,et al.  Polymorph control: past, present and future. , 2008, Drug discovery today.

[77]  Y. Guo,et al.  Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. , 2000, Journal of pharmaceutical sciences.

[78]  J. Rantanen,et al.  Insight into Thermally Induced Phase Transformations of Erythromycin A Dihydrate , 2006 .

[79]  Lynne S Taylor,et al.  Hyphenation of Raman spectroscopy with gravimetric analysis to interrogate water-solid interactions in pharmaceutical systems. , 2007, Journal of pharmaceutical and biomedical analysis.

[80]  H. Ando,et al.  Analysis of known crystals to design polymorph prediction strategies. , 2007, Journal of pharmaceutical sciences.

[81]  Hierarchies of Intermolecular Potentials and Forces: Progress Towards a Quantitative Evaluation , 2005 .

[82]  T. Rades,et al.  Determination of polymorphic forms of ranitidine-HCl by DRIFTS and XRPD. , 2001, Journal of pharmaceutical and biomedical analysis.

[83]  A. Gavezzotti,et al.  Computer simulations and analysis of structural and energetic features of some crystalline energetic materials. , 2007, The journal of physical chemistry. B.

[84]  R. Davey,et al.  Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole , 1998 .

[85]  M. Mazzotti,et al.  In Situ Monitoring and Modeling of the Solvent-Mediated Polymorphic Transformation of l-Glutamic Acid , 2006 .

[86]  Danielle Giron,et al.  Solid-state of pharmaceutical compounds , 2004 .

[87]  P. Paronen,et al.  Dynamic solid-state and tableting properties of four theophylline forms. , 2001, International journal of pharmaceutics.

[88]  J. C. Guyot,et al.  A new pure paracetamol for direct compression : the orthorhombic form. , 1996 .

[89]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[90]  M. Kitamura,et al.  Controlling factor of polymorphism in crystallization process , 2002 .

[91]  Thomas Rades,et al.  Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[92]  J. Swarbrick,et al.  Encyclopedia of Pharmaceutical Technology , 2006 .

[93]  A. Gavezzotti Quantitative Ranking of Crystal Packing Modes by Systematic Calculations on Potential Energies and Vibrational Amplitudes of Molecular Dimers. , 2005, Journal of chemical theory and computation.

[94]  A. Gavezzotti,et al.  Molecular recognition in organic crystals: directed intermolecular bonds or nonlocalized bonding? , 2005, Angewandte Chemie.

[95]  Sarah L Price,et al.  From crystal structure prediction to polymorph prediction: interpreting the crystal energy landscape. , 2008, Physical chemistry chemical physics : PCCP.

[96]  P. Karamertzanis,et al.  Racemic progesterone: predicted in silico and produced in the solid state. , 2006, Chemical communications.

[97]  P. Taday,et al.  Understanding the influence of polymorphism on phonon spectra: lattice dynamics calculations and terahertz spectroscopy of carbamazepine. , 2006, The journal of physical chemistry. B.

[98]  Jeanette T. Dunlap,et al.  A metastable polymorph of metformin hydrochloride: Isolation and characterization using capillary crystallization and thermal microscopy techniques , 2004 .

[99]  Johanna Smeyers-Verbeke,et al.  Handbook of Chemometrics and Qualimetrics: Part A , 1997 .

[100]  W. Tong,et al.  Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.

[101]  N. Redman-Furey,et al.  Statistical cluster analysis of pharmaceutical solvents. , 2007, International journal of pharmaceutics.

[102]  J. Mullin Industrial techniques and equipment , 2001 .

[103]  Sharmistha Datta,et al.  Crystal structures of drugs: advances in determination, prediction and engineering , 2004, Nature reviews. Drug discovery.

[104]  I. Miroshnyk,et al.  Influence of solvents on the variety of crystalline forms of erythromycin , 2003, AAPS PharmSci.

[105]  David J. Willock,et al.  The relaxation of molecular crystal structures using a distributed multipole electrostatic model , 1995, J. Comput. Chem..

[106]  Glen Spraggon,et al.  Computational analysis of crystallization trials. , 2002, Acta crystallographica. Section D, Biological crystallography.

[107]  R. Docherty,et al.  Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformational Mimicry , 1997 .

[108]  T. Rades,et al.  Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride. , 1999, International journal of pharmaceutics.

[109]  M. Otsuka,et al.  Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry. , 2001, The Analyst.

[110]  Rasmus Bro,et al.  Exploring complex interactions in designed data using GEMANOVA. Color changes in fresh beef during storage , 2002 .

[111]  David E. Bugay,et al.  Physical Characterization of Pharmaceutical Solids , 1995, Pharmaceutical Research.

[112]  L. Howard Use of Patents in Drug Lifecycle Management , 2007 .

[113]  S. L. Mayo,et al.  DREIDING: A generic force field for molecular simulations , 1990 .

[114]  H. Aboul‐Enein,et al.  Analysis of mebendazole polymorphs by Fourier transform IR spectrometry using chemometric methods. , 2002, Biopolymers.

[115]  B. Freiermuth,et al.  Polymorphism - integrated approach from high-throughput screening to crystallization optimization , 2003 .

[116]  Christopher T. Walsh,et al.  Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.

[117]  R. Davey,et al.  From Molecules to Crystallizers: An Introduction to Crystallization , 2000 .

[118]  B. Shekunov,et al.  CRYSTALLIZATION PROCESSES IN PHARMACEUTICAL TECHNOLOGY AND DRUG DELIVERY DESIGN , 2000 .

[119]  L Yu,et al.  Amorphous pharmaceutical solids: preparation, characterization and stabilization. , 2001, Advanced drug delivery reviews.

[120]  Jukka Rantanen,et al.  Hyphenated spectroscopy as a polymorph screening tool. , 2007, Journal of pharmaceutical and biomedical analysis.

[121]  G. Day,et al.  Atomistic calculations of phonon frequencies and thermodynamic quantities for crystals of rigid organic molecules , 2003 .

[122]  Claus Cornett,et al.  Solvent subset selection for polymorph screening , 2008 .

[123]  Steve Lowry,et al.  Integrating a Raman Microscope into the Workflow of a High-Throughput Crystallization Laboratory , 2006 .

[124]  W. Addicks,et al.  Polymorphism in generic drug product development. , 2004, Advanced drug delivery reviews.

[125]  J. Anwar,et al.  Crystallization of polymorphs : the effect of solvent , 1993 .

[126]  A. Gavezzotti,et al.  Ten years of experience in polymorph prediction: what next? , 2002 .

[127]  M. Kemper,et al.  Quantitative analysis of polymorphs in binary and multi-component powder mixtures by near-infrared reflectance spectroscopy. , 2000, International journal of pharmaceutics.

[128]  David J W Grant,et al.  Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.

[129]  K. Raghavan,et al.  Grouping solvents by statistical analysis of solvent property parameters: implication to polymorph screening. , 2004, International journal of pharmaceutics.

[130]  R. Davey Crystallization: How come you look so good? , 2004, Nature.

[131]  A. Matzger,et al.  Form IV of carbamazepine. , 2002, Journal of pharmaceutical sciences.

[132]  Michael J. Cima,et al.  Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[133]  Sarah L. Price,et al.  Energy minimization of crystal structures containing flexible molecules , 2006 .

[134]  J. Guillory GENERATION OF POLYMORPHS, HYDRATES, SOLVATES, AND AMORPHOUS SOLIDS , 1999 .

[135]  W. Curatolo,et al.  Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.

[136]  Stephen R. Byrn,et al.  Crystal structure, solid-state NMR spectra, and oxygen reactivity of five crystal forms of prednisolone tert-butylacetate , 1988 .

[137]  H. Brittain Polymorphism in Pharmaceutical Solids , 1999 .

[138]  Jukka Rantanen,et al.  In situ measurement of solvent-mediated phase transformations during dissolution testing. , 2006, Journal of pharmaceutical sciences.

[139]  K. Gordon,et al.  Quantitative analysis of polymorphic mixtures of ranitidine hydrochloride by Raman spectroscopy and principal components analysis. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[140]  Thomas Rades,et al.  Quantitative analysis of polymorphic mixtures of carbamazepine by Raman spectroscopy and principal components analysis , 2004 .

[141]  Chemometrics Approach to the Determination of Polymorphism of a Drug Compound by Infrared Spectroscopy , 2000, Drug development and industrial pharmacy.

[142]  Vinod P. Shah,et al.  The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures , 1992, Pharmaceutical Research.

[143]  G. Buckton,et al.  The novel combination of dynamic vapour sorption gravimetric analysis and near infra-red spectroscopy as a hyphenated technique. , 2000, International journal of pharmaceutics.